[1]钟 亮,刘清壮,蔡茂德.III、IV期上皮性卵巢癌术后腹腔辅助化疗临床观察*[J].陕西医学杂志,2020,49(2):193-196.
　ZHONG Liang,LIU Qingzhuang,CAI Maode..Application of intraperitoneal chemotherapy in postoperative adjuvant treatment of stage Ⅲ and Ⅳ epithelial ovarian cancer[J].,2020,49(2):193-196.
点击复制

III、IV期上皮性卵巢癌术后腹腔辅助化疗临床观察*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年2期
页码:
193-196
栏目:
临床研究
出版日期:
2020-02-05

文章信息/Info

Title:
Application of intraperitoneal chemotherapy in postoperative adjuvant treatment of stage Ⅲ and Ⅳ epithelial ovarian cancer
文章编号:
DOI:〖HT5K〗10.3969/j.issn.10007377.2020.02.018
作者:
钟 亮; 刘清壮; 蔡茂德
广东省高州市人民医院肿瘤内科(高州 525200)
Author(s):
ZHONG Liang; LIU Qingzhuang; CAI Maode.
Department of Oncology,Gaozhou People's Hospital,Guangdong Province(Gaozhou 525200)
关键词:
上皮性卵巢癌;  腹腔化疗;  静脉化疗;  疗效;  安全性;  肿瘤标志物
Keywords:
Epithelial ovarian cancer;  Intraperitoneal chemotherapy;  Intravenous chemotherapy;  Efficacy;  Safety;  Tumor marker
分类号:
R737.31
文献标志码:
A
摘要:
目的:探讨腹腔化疗在III、IV期上皮性卵巢癌术后辅助治疗中的疗效与安全性。方法:选取获得满意肿瘤细胞减灭术的 102 例Ⅲ、Ⅳ期上皮性卵巢癌患者,随机分为观察组(51例)和对照组(51例)。对照组给予静脉化疗,观察组给予腹腔化疗联合静脉化疗; 对比两组近期疗效、血清肿瘤标志物水平、毒副作用及预后。结果:治疗6个周期后,观察组治疗有效率(52.9%)明显高于对照组(33.3%)(P<0.05); 治疗6个周期后,观察组血清CA125(34.62±3.07)U/ml、HE4(107.23±20.76)pmol/L、TPA(53.51±4.02)U/L水平明显低于对照组CA125(38.81±3.36)U/ml、HE4(168.36±31.54)pmol/L、TPA(63.18±4.18)U/L(P<0.05); 化疗6周期后,观察组不同类型毒副反应发生率与对照组比较无统计学差异(P<0.05); 随访2年,观察组中位生存时间(34个月)明显长于对照组(27个月)(P<0.05)。结论:腹腔化疗联合静脉化疗在III、IV期上皮性卵巢癌术后辅助治疗中疗效较单纯静脉化疗更好,可明显降低患者血清标志物水平,且化疗毒副作用无明显增加,延长了患者的中位生存时间。
Abstract:
Objective:To investigate the efficacy and safety of intraperitoneal chemotherapy in the adjuvant treatment of stage Ⅲ and Ⅳ epithelial ovarian cancer. Methods:A total of 102 patients with stage Ⅲ and Ⅳ epithelial ovarian cancer who obtained satisfactory tumor cytoreductive surgery were randomly divided into observation group(51 cases)and control group(51 cases). The control group was given intravenous chemotherapy,and the observation group was given intraperitoneal chemotherapy combined with intravenous chemotherapy. The short-term efficacy,serum marker levels,toxic side effects and prognosis were compared between the two groups. Results:After 6 cycles of treatment,the effective rate of the observation group(52.9%)was significantly higher than that of the control group(33.3%)(P<0.05). After 6 cycles of treatment,the serum CA125 [(34.62±3.07)U/ml],HE4 [(107.23±20.76)pmol/L] and TPA [(53.51±4.02)U/L] in the observation group were significantly lower than CA125 [(38.81±3.36)U/ml],HE4 [(168.36±31.54)pmol/L],and TPA [(63.18±4.18)U/L] in control group(P<0.05). After 6 cycles of chemotherapy,the incidence rate of different types of toxic side effects in the observation group was not significantly different from that in the control group(P<0.05). Followed up for 2 years,the median survival time of the observation group(34 months)was significantly longer than that of the control group(27 months)(P<0.05). Conclusion:Intraperitoneal chemotherapy combined with intravenous chemotherapy is better than intravenous chemotherapy alone in postoperative adjuvant treatment of stage Ⅲ and Ⅳ epithelial ovarian cancer. It can significantly reduce the serum marker levels,and the toxic side effects of chemotherapy are not significantly increased. It can prolong the median survival time of patients.

参考文献/References:

[1] 李 晓,戢清荣.调经种玉丸治疗肾虚血瘀型卵巢储备功能下降临床研究[J].陕西中医,2019,40(9):1216-1218.
[2] 杨 勇,王 冰.人绒毛膜促性腺激素、人附睾蛋白4、糖类抗原199联合检测对卵巢肿瘤的诊断价值[J].陕西医学杂志,2019,48(8):1091-1093,1101.
[3] Miller EM,Tymon-Rosario J,Xie X,et al.Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer:A 10-year single institution experience with a racially diverse urban population[J]. Gynecol Oncol,2017,147(1):36-40.
[4] 席艳妮,王成宏,刘聪荣,等. 新辅助化疗联合肿瘤细胞减灭术及术后腹腔热灌注化疗在晚期卵巢癌治疗中的应用价值分析[J]. 癌症进展,2017,15(12):1473-1476.
[5] Provencher DM,Gallagher CJ,Parulekar WR,et al.OV21/PETROC:a randomized gynecologic cancer intergroup phase ii study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer[J]. Obstetrical and Gynecological Survey,2018,73(4):209-210.
[6] 孙建华,姬忠贺,李 雁. 细胞减灭术加腹腔热灌注化疗治疗复发性卵巢癌[J]. 肿瘤学杂志,2018,24(3):240-246.
[7] 付立业,田 昕,李 妍,等. 血清人附睾分泌蛋白4(HE4)和CA125在卵巢癌患者围手术期的变化及临床意义[J]. 现代肿瘤医学,2017,21(20):96-99.
[8] Padmakumar S,Parayath N,Leslie F,et al. Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices[J]. Expert Opin Drug Deliv,2018,15(5):481-494.
[9] Piso P,Dahlke MH,Loss M,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer[J]. Journal of Surgical Oncology,2017,116(3):21-21.
[10] 孙红艳,王改华.不同手术方式治疗卵巢癌临床效果及对患者生育功能的影响[J].陕西医学杂志,2019,48(2):213-216.
[11] Miailhe G,Arfi A,Mirshahi M,et al.A new animal model for hyperthermic intraperitoneal chemotherapy(HIPEC)in tumor-bearing mice in the treatment of peritoneal carcinomatosis of ovarian origin[J]. J Visc Surg,2018,155(3):183-189.
[12] 李天春,罗 辉. 新辅助化疗治疗晚期卵巢癌患者的疗效观察[J]. 贵州医药,2018,42(2):195-197.
[13] Du F,Li P,Chen J,et al. Adjuvant chemotherapy with bevacizumab(i.p.)can prolong survival time of patients with advanced ovarian cancer after cytoreduction[J]. Neoplasma,2017,64(1):108-113.
[14] 贾慧珣,李 俊,史庭燕. 晚期卵巢癌中间型瘤体减灭术+腹腔热灌注化疗对比单纯中间型瘤体减灭术研究解读[J]. 中国癌症杂志,2018,28(10):65-71.
[15] Deshayes E,Ladjohounlou R,Le Fur P,et al. Anti-MISRII radiolabeled antibodies:new tools for a theranostic approach in ovarian cancer[J]. J Nucl Med,2018,59(8):1234-1242.
[16] 刘 力,王会茹,王道芝.卵巢癌腹腔化疗3种方式的探讨[J].陕西医学杂志,2002,31(5):401-402.
[17] 郭 艳,陈友国. 晚期上皮性卵巢癌三种腹腔化疗方案的疗效和安全性比较[J]. 现代医学,2017,17(3):126-128.
[18] 侯晓茹,郭田田,秦 峰. 新辅助化疗联合中间性肿瘤细胞减灭术治疗晚期上皮性卵巢癌的疗效及对HE4、VEGF、CA125水平的影响[J]. 癌症进展,2018,16(6):62-65.

相似文献/References:

[1]孙红艳,王改华.不同手术方式治疗卵巢癌临床效果及对患者生育功能的影响[J].陕西医学杂志,2019,(2):213.
　SUN Hongyan,WANG Gaihua..Clinical effects of different surgical treatments on 125 patients with ovarian  cancer and their influence on reproductive function[J].,2019,(2):213.
[2]王 琰,王 静,张志明,等.卵巢肿瘤患者尿液中间皮素联合人附睾蛋白4检测及临床意义[J].陕西医学杂志,2019,(8):1088.
　WANG Yan,WANG Jing,ZHANG Zhiming,et al.Predictive value between MSLN and HE4 in urine levels in patients with  early stage of epithelial ovarian cancer[J].,2019,(2):1088.
[3]张晶晶,岳丽娟,王 莹,等.奥拉帕利联合奈达铂腹腔热灌注化疗治疗上皮性卵巢癌疗效观察[J].陕西医学杂志,2021,50(12):1566.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.025]
　ZHANG Jingjing,YUE Lijuan,WANG Ying,et al.Efficacy of olaparib combined with nedaplatin hyperthermic intraperitoneal chemotherapy in treatment of epithelial ovarian cancer[J].,2021,50(2):1566.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.025]
[4]孙丹丹,张 颖,马善波,等.膜相关环指蛋白7在上皮性卵巢癌组织和细胞中的表达及作用机制研究[J].陕西医学杂志,2024,(6):842.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.026]
　SUN Dandan,ZHANG Ying,MA Shanbo,et al.Expression and mechanism of membrane-associated ring finger protein 7 in epithelial ovarian cancer tissues and cells[J].,2024,(2):842.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.026]

备注/Memo

备注/Memo:
*广东省茂名市科技立项项目(2018135)
更新日期/Last Update: 2020-03-25